Sweden · Delayed Price · Currency is SEK Paxman AB Earnings Call Transcripts
Fiscal Year 2026
-
Significant growth in 2025 was driven by a major acquisition, record sales, and a strategic shift to insurance-based billing in the US. Regulatory progress and new product launches are set to accelerate growth, with a focus on operational excellence and expanding standard of care globally.
Fiscal Year 2025
-
Q4 saw strong sales growth driven by the Dignitana acquisition and robust U.S. insurance-based billing, with group net sales up to SEK 84 million. Strategic focus is on U.S. expansion, new product launches, and leveraging CPT I codes for improved reimbursement.
-
The company is rapidly expanding in medtech, focusing on cryotherapy for chemotherapy side effects and transitioning to an insurance-based billing model to drive U.S. growth. Key priorities include integrating a major competitor, launching new products, and leveraging legislative changes for broader insurance coverage by 2026.
-
Key strategic priorities include accelerating the insurance-based billing model, launching new alopecia and neuropathy products, and expanding U.S. and select international markets. Strong clinical data and regulatory progress support commercialization, while the Dignitana integration enhances scale and profitability. Focus remains on operational excellence, patient impact, and sustainable growth.
-
Record Q3 revenue driven by Dignitana integration and strong US focus, with EBITDA margin at 9%. CIPN commercialization and insurance-based billing remain key growth drivers, while legislative and regulatory developments support future expansion.
-
Sales grew 17% year-over-year, driven by the Dignitana acquisition and strong international demand. Integration and restructuring are on track, with cost synergies and improved margins expected by year-end. Cash reserves remain robust at over SEK 149 million.
-
Achieved record Q1 sales with 14.5% growth and strong U.S. performance, but reported a forex-driven net loss. Completed the Dignitana merger, raised SEK 120 million, and advanced U.S. reimbursement and CIPN commercialization initiatives.